Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazodalibep in Sjögren's Syndrome with moderate-to-severe symptoms
NCT06245408Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of dazodalibep in Sjögren's syndrome (3 arms), sponsored by Amgen. Primary endpoints: EULAR Sjögren's Syndrome Patient Reported Index at 48 weeks and Diary for Assessing Sjogren's Patient Reported Index at 48 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06245408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245408.